GT200800296A - Derivados de ácido fenilacético - Google Patents

Derivados de ácido fenilacético

Info

Publication number
GT200800296A
GT200800296A GT200800296A GT200800296A GT200800296A GT 200800296 A GT200800296 A GT 200800296A GT 200800296 A GT200800296 A GT 200800296A GT 200800296 A GT200800296 A GT 200800296A GT 200800296 A GT200800296 A GT 200800296A
Authority
GT
Guatemala
Prior art keywords
derivatives
phenylactic acid
phenylactic
same
acid
Prior art date
Application number
GT200800296A
Other languages
English (en)
Inventor
Lauren G Monovich
Mugrage Benjamin Biro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667003&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800296(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200800296A publication Critical patent/GT200800296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains

Abstract

SE DESCRIBEN COMPUESTOS DE LA FÓRMULA (I), SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, Y ÉSTERES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, LOS CUALES SON ÚTILES PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE COX-2. T2008
GT200800296A 2006-06-26 2008-12-17 Derivados de ácido fenilacético GT200800296A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80578406P 2006-06-26 2006-06-26

Publications (1)

Publication Number Publication Date
GT200800296A true GT200800296A (es) 2009-03-19

Family

ID=38667003

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800296A GT200800296A (es) 2006-06-26 2008-12-17 Derivados de ácido fenilacético

Country Status (27)

Country Link
US (3) US8362294B2 (es)
EP (1) EP2046723B1 (es)
JP (1) JP5258761B2 (es)
KR (1) KR101380423B1 (es)
CN (1) CN101479231A (es)
AR (2) AR061623A1 (es)
AU (1) AU2007265181B2 (es)
BR (1) BRPI0713523A8 (es)
CA (1) CA2655676C (es)
CL (1) CL2007001857A1 (es)
CR (1) CR10506A (es)
EC (1) ECSP088988A (es)
ES (1) ES2386989T3 (es)
GT (1) GT200800296A (es)
IL (1) IL195958A (es)
MA (1) MA30567B1 (es)
MX (1) MX2008016337A (es)
MY (1) MY145122A (es)
NO (1) NO20090292L (es)
PE (1) PE20080213A1 (es)
PL (1) PL2046723T3 (es)
PT (1) PT2046723E (es)
RU (1) RU2454402C2 (es)
TN (1) TNSN08531A1 (es)
TW (1) TW200817309A (es)
WO (1) WO2008002853A2 (es)
ZA (1) ZA200810562B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156809B2 (en) 1999-12-17 2007-01-02 Q-Tec Systems Llc Method and apparatus for health and disease management combining patient data monitoring with wireless internet connectivity
WO2011101321A1 (de) 2010-02-19 2011-08-25 Bayer Cropscience Ag 3-aminocarbonyl substituierte benzoylcyclohexandione und ihre verwendung als herbizide
JP6250893B2 (ja) * 2015-02-13 2017-12-20 トヨタ自動車株式会社 ブローバイガス処理装置およびインテークマニホールド
CN105669732B (zh) * 2016-01-10 2017-05-31 沧州普瑞东方科技有限公司 一种合成4‑氟‑5‑异丙基‑2‑甲氧基苯硼酸的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133740C (es) 1965-04-08
SE366296B (es) 1967-12-20 1974-04-22 Ciba Geigy Ag
JPS51149252A (en) 1975-06-14 1976-12-22 Ikeda Mohandou:Kk A process for preparing naphthylaminophenyl acetic acid derivatives
US4001878A (en) 1975-11-19 1977-01-04 Rca Corporation Charge transfer color imagers
JPS5268159A (en) 1975-12-03 1977-06-06 Ikeda Mohando Co Production of naphthyl aminophenyl acetic acid derivatives
JPS5283822A (en) 1976-01-01 1977-07-13 Ikeda Mohando Co Naphthylaminopheny acetic acid derivatives and salts thereof*
JPS5770848A (en) * 1980-10-20 1982-05-01 Zenyaku Kogyo Kk Preparation of o-substituted phenylacetic acid
CH650766A5 (en) 1980-10-20 1985-08-15 Zenyaku Kogyo Kk Process for preparing o-(2,6-Dichloroanilino)phenylacetic acid
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US6355680B1 (en) * 1996-02-20 2002-03-12 Exocell, Inc. Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
CZ20014366A3 (cs) 1999-06-10 2002-11-13 Warner-Lambert Company Způsob inhibice agregace amyloidních proteinů a zobrazení amyloidních usazenin za pouľití isoindolinových derivátů
GB9922830D0 (en) 1999-09-27 1999-11-24 Novartis Ag Processes
US20030087942A1 (en) * 2001-08-31 2003-05-08 Washington University Method for the treatment and prevention of cachexia
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
EP1674526B9 (en) 2003-10-01 2013-05-29 Polyplastics Co., Ltd. Polyacetal resin composition
EP2224472B8 (en) 2007-12-17 2014-03-19 JX Nippon Mining & Metals Corporation Substrate and method for manufacturing the same

Also Published As

Publication number Publication date
BRPI0713523A2 (pt) 2012-02-14
CR10506A (es) 2009-02-02
NO20090292L (no) 2009-01-26
US20140058129A1 (en) 2014-02-27
CA2655676A1 (en) 2008-01-03
CN101479231A (zh) 2009-07-08
IL195958A (en) 2016-09-29
ECSP088988A (es) 2009-01-30
KR20090025366A (ko) 2009-03-10
PL2046723T3 (pl) 2012-12-31
US8362294B2 (en) 2013-01-29
WO2008002853A3 (en) 2008-02-07
CL2007001857A1 (es) 2008-06-13
MY145122A (en) 2011-12-30
TW200817309A (en) 2008-04-16
TNSN08531A1 (en) 2010-04-14
JP5258761B2 (ja) 2013-08-07
PE20080213A1 (es) 2008-05-08
ZA200810562B (en) 2009-11-25
IL195958A0 (en) 2009-09-22
AR061623A1 (es) 2008-09-10
PT2046723E (pt) 2012-09-20
JP2009541487A (ja) 2009-11-26
WO2008002853A2 (en) 2008-01-03
EP2046723B1 (en) 2012-07-18
RU2009102271A (ru) 2010-08-10
KR101380423B1 (ko) 2014-04-01
CA2655676C (en) 2014-07-22
ES2386989T3 (es) 2012-09-10
AR108389A2 (es) 2018-08-15
BRPI0713523A8 (pt) 2018-05-02
AU2007265181B2 (en) 2010-11-25
AU2007265181A1 (en) 2008-01-03
MA30567B1 (fr) 2009-07-01
MX2008016337A (es) 2009-01-16
RU2454402C2 (ru) 2012-06-27
US20130012585A1 (en) 2013-01-10
US20090209648A1 (en) 2009-08-20
US8586782B2 (en) 2013-11-19
EP2046723A2 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
EA201170872A1 (ru) Ингибиторы протеинкиназы
UY30500A1 (es) Compuestos de azabencimidazolilo
NO20083726L (no) Spiroindolinon derivater
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
UY33075A (es) Derivados de ciclohexano y usos de los mismos
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
GT200600117A (es) Nuevos compuestos farmaceuticos
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
CR11824A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
DOP2010000197A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
UY30424A1 (es) Derivados de quinolina, su preparacion, su uso y medicamentos que comprenden los mismos.